1071 related articles for article (PubMed ID: 24670641)
1. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.
Chen X; Iliopoulos D; Zhang Q; Tang Q; Greenblatt MB; Hatziapostolou M; Lim E; Tam WL; Ni M; Chen Y; Mai J; Shen H; Hu DZ; Adoro S; Hu B; Song M; Tan C; Landis MD; Ferrari M; Shin SJ; Brown M; Chang JC; Liu XS; Glimcher LH
Nature; 2014 Apr; 508(7494):103-107. PubMed ID: 24670641
[TBL] [Abstract][Full Text] [Related]
2. EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1α pathway.
Qiu Z; Guo W; Dong B; Wang Y; Deng P; Wang C; Liu J; Zhang Q; Grosschedl R; Yu Z; Deng J; Wu Y
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2119518119. PubMed ID: 35867755
[TBL] [Abstract][Full Text] [Related]
3. Hallmarks of triple negative breast cancer emerging at last?
Bernardi R; Gianni L
Cell Res; 2014 Aug; 24(8):904-5. PubMed ID: 24810303
[TBL] [Abstract][Full Text] [Related]
4. Hypoxic ER stress suppresses β-catenin expression and promotes cooperation between the transcription factors XBP1 and HIF1α for cell survival.
Xia Z; Wu S; Wei X; Liao Y; Yi P; Liu Y; Liu J; Liu J
J Biol Chem; 2019 Sep; 294(37):13811-13821. PubMed ID: 31350332
[TBL] [Abstract][Full Text] [Related]
5. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
7. ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling.
Liu Y; Su P; Zhao W; Li X; Yang X; Fan J; Yang H; Yan C; Mao L; Ding Y; Zhu J; Niu Z; Zhuang T
Cancer Sci; 2021 Jul; 112(7):2714-2727. PubMed ID: 33939216
[TBL] [Abstract][Full Text] [Related]
8. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes.
Jiang D; Turner B; Song J; Li R; Diehn M; Le QT; Khatri P; Koong AC
JCO Precis Oncol; 2017; 2017():. PubMed ID: 29888341
[TBL] [Abstract][Full Text] [Related]
11. IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment.
Harnoss JM; Le Thomas A; Reichelt M; Guttman O; Wu TD; Marsters SA; Shemorry A; Lawrence DA; Kan D; Segal E; Merchant M; Totpal K; Crocker LM; Mesh K; Dohse M; Solon M; Modrusan Z; Rudolph J; Koeppen H; Walter P; Ashkenazi A
Cancer Res; 2020 Jun; 80(11):2368-2379. PubMed ID: 32265225
[TBL] [Abstract][Full Text] [Related]
12. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
13. The balance between adaptive and apoptotic unfolded protein responses regulates β-cell death under ER stress conditions through XBP1, CHOP and JNK.
Chan JY; Luzuriaga J; Maxwell EL; West PK; Bensellam M; Laybutt DR
Mol Cell Endocrinol; 2015 Sep; 413():189-201. PubMed ID: 26135354
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional induction of the human asparagine synthetase gene during the unfolded protein response does not require the ATF6 and IRE1/XBP1 arms of the pathway.
Gjymishka A; Su N; Kilberg MS
Biochem J; 2009 Feb; 417(3):695-703. PubMed ID: 18840095
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
Zhang FL; Cao JL; Xie HY; Sun R; Yang LF; Shao ZM; Li DQ
Cancer Res; 2018 Oct; 78(20):5780-5792. PubMed ID: 30093560
[TBL] [Abstract][Full Text] [Related]
16. ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer.
Fang W; Liao C; Shi R; Simon JM; Ptacek TS; Zurlo G; Ye Y; Han L; Fan C; Bao L; Ortiz CL; Lin HR; Manocha U; Luo W; Peng Y; Kim WY; Yang LW; Zhang Q
Elife; 2021 Nov; 10():. PubMed ID: 34779768
[TBL] [Abstract][Full Text] [Related]
17. NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2α-ATF4 signalling in breast cancer.
Gupta A; Hossain MM; Miller N; Kerin M; Callagy G; Gupta S
Oncogene; 2016 Nov; 35(45):5860-5871. PubMed ID: 27109102
[TBL] [Abstract][Full Text] [Related]
18. Adaptive unfolded protein response attenuates alcohol-induced pancreatic damage.
Lugea A; Tischler D; Nguyen J; Gong J; Gukovsky I; French SW; Gorelick FS; Pandol SJ
Gastroenterology; 2011 Mar; 140(3):987-97. PubMed ID: 21111739
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer.
Tang X; Zhou Y; Liu Y; Zhang W; Liu C; Yan C
J Cell Biochem; 2020 Nov; 121(11):4642-4653. PubMed ID: 32048750
[TBL] [Abstract][Full Text] [Related]
20. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
